| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteogenesis | 63 | 2025 | 273 | 9.240 |
Why?
|
| Growth Differentiation Factor 2 | 51 | 2024 | 155 | 6.770 |
Why?
|
| Cell Differentiation | 84 | 2025 | 1610 | 6.590 |
Why?
|
| Osteosarcoma | 24 | 2022 | 158 | 4.090 |
Why?
|
| Cell Proliferation | 74 | 2024 | 1735 | 3.480 |
Why?
|
| Stem Cells | 28 | 2024 | 386 | 3.300 |
Why?
|
| Growth Differentiation Factors | 19 | 2019 | 56 | 3.200 |
Why?
|
| Signal Transduction | 64 | 2024 | 3498 | 3.190 |
Why?
|
| Adenoviridae | 29 | 2018 | 340 | 2.900 |
Why?
|
| beta Catenin | 27 | 2022 | 265 | 2.820 |
Why?
|
| Mice | 152 | 2025 | 12233 | 2.710 |
Why?
|
| Tissue Scaffolds | 13 | 2025 | 128 | 2.670 |
Why?
|
| Genetic Vectors | 22 | 2019 | 422 | 2.590 |
Why?
|
| Wnt Proteins | 16 | 2017 | 127 | 2.490 |
Why?
|
| Osteoblasts | 16 | 2020 | 96 | 2.420 |
Why?
|
| Bone Morphogenetic Proteins | 22 | 2016 | 131 | 2.400 |
Why?
|
| Bone Neoplasms | 18 | 2022 | 313 | 2.230 |
Why?
|
| Animals | 192 | 2025 | 28041 | 2.220 |
Why?
|
| Wnt Signaling Pathway | 11 | 2022 | 103 | 2.130 |
Why?
|
| MicroRNAs | 11 | 2023 | 580 | 2.070 |
Why?
|
| Mice, Nude | 45 | 2021 | 824 | 2.000 |
Why?
|
| Cell Line, Tumor | 66 | 2025 | 2756 | 1.990 |
Why?
|
| Cell Line | 59 | 2022 | 2459 | 1.910 |
Why?
|
| HEK293 Cells | 38 | 2020 | 696 | 1.850 |
Why?
|
| Hepatocytes | 14 | 2019 | 129 | 1.710 |
Why?
|
| RNA, Long Noncoding | 8 | 2022 | 129 | 1.580 |
Why?
|
| Gene Expression Regulation, Neoplastic | 28 | 2024 | 1339 | 1.490 |
Why?
|
| Humans | 230 | 2025 | 93615 | 1.440 |
Why?
|
| Transduction, Genetic | 12 | 2017 | 160 | 1.430 |
Why?
|
| RNA, Small Interfering | 11 | 2022 | 555 | 1.340 |
Why?
|
| Bone Regeneration | 11 | 2025 | 65 | 1.340 |
Why?
|
| Amyloid beta-Protein Precursor | 3 | 2022 | 148 | 1.330 |
Why?
|
| Tissue Engineering | 7 | 2025 | 202 | 1.320 |
Why?
|
| Gene Expression Regulation | 19 | 2020 | 1980 | 1.290 |
Why?
|
| Apoptosis | 41 | 2023 | 1719 | 1.270 |
Why?
|
| Antineoplastic Agents | 16 | 2024 | 2302 | 1.260 |
Why?
|
| Cells, Cultured | 38 | 2025 | 2828 | 1.230 |
Why?
|
| Craniosynostoses | 7 | 2023 | 71 | 1.220 |
Why?
|
| Cell Movement | 28 | 2021 | 804 | 1.190 |
Why?
|
| S100 Proteins | 4 | 2015 | 51 | 1.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 6 | 2017 | 192 | 1.150 |
Why?
|
| Bone and Bones | 10 | 2024 | 269 | 1.130 |
Why?
|
| Receptors, Notch | 2 | 2019 | 138 | 1.110 |
Why?
|
| Endothelial Cells | 6 | 2025 | 477 | 1.030 |
Why?
|
| Gene Transfer Techniques | 8 | 2015 | 154 | 1.030 |
Why?
|
| STAT Transcription Factors | 2 | 2020 | 18 | 1.000 |
Why?
|
| RNA Interference | 11 | 2021 | 379 | 0.980 |
Why?
|
| Trans-Activators | 11 | 2005 | 439 | 0.980 |
Why?
|
| Panax | 15 | 2017 | 171 | 0.980 |
Why?
|
| Hydrogels | 3 | 2025 | 92 | 0.970 |
Why?
|
| Cytoskeletal Proteins | 10 | 2005 | 222 | 0.940 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2018 | 26 | 0.910 |
Why?
|
| Neoplasms | 12 | 2024 | 3171 | 0.910 |
Why?
|
| Transfection | 17 | 2021 | 878 | 0.910 |
Why?
|
| Cranial Sutures | 5 | 2020 | 44 | 0.900 |
Why?
|
| Monensin | 3 | 2023 | 16 | 0.900 |
Why?
|
| Neovascularization, Pathologic | 4 | 2022 | 353 | 0.900 |
Why?
|
| Bone Morphogenetic Protein 2 | 8 | 2025 | 62 | 0.890 |
Why?
|
| Cell Cycle Proteins | 5 | 2015 | 409 | 0.890 |
Why?
|
| Protein-Tyrosine Kinases | 9 | 2013 | 302 | 0.890 |
Why?
|
| Liver | 9 | 2019 | 1207 | 0.880 |
Why?
|
| Colorectal Neoplasms | 25 | 2023 | 1054 | 0.880 |
Why?
|
| Fibroblasts | 8 | 2018 | 752 | 0.870 |
Why?
|
| Gene Expression | 16 | 2019 | 1302 | 0.840 |
Why?
|
| Antigens, Polyomavirus Transforming | 4 | 2018 | 48 | 0.840 |
Why?
|
| Transcription Factors | 10 | 2024 | 1690 | 0.820 |
Why?
|
| Up-Regulation | 19 | 2021 | 729 | 0.780 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2025 | 83 | 0.770 |
Why?
|
| Intervertebral Disc | 8 | 2025 | 30 | 0.760 |
Why?
|
| Pyrvinium Compounds | 1 | 2022 | 5 | 0.750 |
Why?
|
| Adipogenesis | 5 | 2021 | 41 | 0.750 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 129 | 0.750 |
Why?
|
| Ginsenosides | 12 | 2016 | 124 | 0.740 |
Why?
|
| Ossification, Heterotopic | 3 | 2021 | 32 | 0.740 |
Why?
|
| Genetic Engineering | 2 | 2017 | 100 | 0.740 |
Why?
|
| Xenograft Model Antitumor Assays | 17 | 2024 | 526 | 0.730 |
Why?
|
| Wnt3A Protein | 6 | 2015 | 23 | 0.710 |
Why?
|
| Drugs, Chinese Herbal | 6 | 2017 | 68 | 0.700 |
Why?
|
| Sapogenins | 4 | 2015 | 25 | 0.690 |
Why?
|
| Viral Proteins | 4 | 2017 | 248 | 0.690 |
Why?
|
| Tretinoin | 8 | 2015 | 128 | 0.690 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 20 | 2022 | 885 | 0.670 |
Why?
|
| Skull | 7 | 2025 | 271 | 0.650 |
Why?
|
| Neoplasm Metastasis | 13 | 2022 | 1061 | 0.650 |
Why?
|
| Plant Extracts | 13 | 2017 | 247 | 0.640 |
Why?
|
| Leptin | 2 | 2020 | 100 | 0.640 |
Why?
|
| Antineoplastic Agents, Phytogenic | 11 | 2016 | 270 | 0.630 |
Why?
|
| Janus Kinases | 1 | 2020 | 24 | 0.630 |
Why?
|
| Cell Division | 13 | 2014 | 690 | 0.620 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2019 | 19 | 0.610 |
Why?
|
| Nerve Regeneration | 1 | 2019 | 34 | 0.610 |
Why?
|
| Myelin Sheath | 1 | 2019 | 66 | 0.590 |
Why?
|
| Carcinogenesis | 4 | 2024 | 235 | 0.590 |
Why?
|
| Bioprinting | 1 | 2019 | 14 | 0.580 |
Why?
|
| Nanoparticles | 5 | 2025 | 198 | 0.570 |
Why?
|
| Real-Time Polymerase Chain Reaction | 10 | 2022 | 296 | 0.560 |
Why?
|
| Neoplasms, Experimental | 3 | 2018 | 260 | 0.560 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2018 | 12 | 0.550 |
Why?
|
| Simian virus 40 | 2 | 2017 | 35 | 0.550 |
Why?
|
| Drug Synergism | 13 | 2018 | 315 | 0.550 |
Why?
|
| Genes, Reporter | 15 | 2017 | 275 | 0.550 |
Why?
|
| Alkaline Phosphatase | 12 | 2021 | 128 | 0.540 |
Why?
|
| Disease Models, Animal | 14 | 2025 | 2491 | 0.540 |
Why?
|
| Genetic Therapy | 9 | 2014 | 366 | 0.540 |
Why?
|
| Cell Survival | 17 | 2018 | 1003 | 0.540 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 2368 | 0.540 |
Why?
|
| Chondrocytes | 8 | 2015 | 60 | 0.540 |
Why?
|
| Male | 55 | 2025 | 44578 | 0.540 |
Why?
|
| Aspartic Acid Endopeptidases | 3 | 2025 | 69 | 0.540 |
Why?
|
| Cell Cycle | 17 | 2021 | 515 | 0.530 |
Why?
|
| Cell Culture Techniques | 6 | 2019 | 196 | 0.530 |
Why?
|
| Phosphoproteins | 3 | 2019 | 259 | 0.530 |
Why?
|
| Gene Expression Profiling | 12 | 2021 | 1516 | 0.530 |
Why?
|
| MAP Kinase Signaling System | 4 | 2025 | 200 | 0.530 |
Why?
|
| Flavonoids | 2 | 2017 | 85 | 0.530 |
Why?
|
| Protein Precursors | 2 | 2017 | 133 | 0.530 |
Why?
|
| Amyloid Precursor Protein Secretases | 3 | 2025 | 98 | 0.530 |
Why?
|
| Microvessels | 1 | 2017 | 68 | 0.520 |
Why?
|
| Pancreatic Neoplasms | 2 | 2025 | 715 | 0.520 |
Why?
|
| Phytotherapy | 6 | 2017 | 137 | 0.520 |
Why?
|
| Multipotent Stem Cells | 2 | 2014 | 20 | 0.520 |
Why?
|
| Biotechnology | 1 | 2017 | 30 | 0.510 |
Why?
|
| Retinoid X Receptors | 5 | 2010 | 38 | 0.510 |
Why?
|
| Biocompatible Materials | 7 | 2024 | 202 | 0.510 |
Why?
|
| Triterpenes | 1 | 2016 | 8 | 0.500 |
Why?
|
| DNA | 5 | 2014 | 1260 | 0.500 |
Why?
|
| Bone Development | 2 | 2008 | 38 | 0.500 |
Why?
|
| Founder Effect | 1 | 2017 | 106 | 0.500 |
Why?
|
| Blotting, Western | 18 | 2018 | 775 | 0.500 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2016 | 16 | 0.500 |
Why?
|
| Neovascularization, Physiologic | 5 | 2024 | 140 | 0.490 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2017 | 201 | 0.490 |
Why?
|
| DNA Transposable Elements | 2 | 2014 | 168 | 0.490 |
Why?
|
| Recombination, Genetic | 5 | 2014 | 419 | 0.490 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2024 | 603 | 0.490 |
Why?
|
| Receptors, Retinoic Acid | 6 | 2012 | 47 | 0.480 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2017 | 129 | 0.480 |
Why?
|
| Colonic Neoplasms | 7 | 2020 | 579 | 0.480 |
Why?
|
| Melanocytes | 2 | 2016 | 60 | 0.480 |
Why?
|
| Green Fluorescent Proteins | 14 | 2019 | 309 | 0.480 |
Why?
|
| Chondrogenesis | 7 | 2025 | 32 | 0.480 |
Why?
|
| Cerebrovascular Circulation | 1 | 2017 | 239 | 0.470 |
Why?
|
| Receptors, Erythropoietin | 5 | 1996 | 14 | 0.450 |
Why?
|
| Cell Adhesion | 9 | 2019 | 416 | 0.450 |
Why?
|
| Transcriptome | 4 | 2022 | 760 | 0.450 |
Why?
|
| NF-kappa B | 7 | 2024 | 408 | 0.450 |
Why?
|
| Female | 60 | 2025 | 48779 | 0.450 |
Why?
|
| Odontogenesis | 4 | 2021 | 15 | 0.450 |
Why?
|
| Melanoma, Experimental | 4 | 2016 | 112 | 0.440 |
Why?
|
| Periodontitis | 2 | 2025 | 8 | 0.440 |
Why?
|
| Neoplasm Transplantation | 10 | 2017 | 400 | 0.440 |
Why?
|
| Femoracetabular Impingement | 2 | 2025 | 14 | 0.440 |
Why?
|
| Neoplasm Invasiveness | 11 | 2018 | 572 | 0.440 |
Why?
|
| HCT116 Cells | 16 | 2019 | 162 | 0.440 |
Why?
|
| Adipocytes | 4 | 2019 | 169 | 0.430 |
Why?
|
| Flow Cytometry | 7 | 2017 | 712 | 0.430 |
Why?
|
| Stem Cell Transplantation | 5 | 2021 | 192 | 0.420 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2013 | 216 | 0.420 |
Why?
|
| Cell Line, Transformed | 7 | 2017 | 152 | 0.420 |
Why?
|
| Hexadimethrine Bromide | 1 | 2014 | 4 | 0.420 |
Why?
|
| Mice, Inbred BALB C | 8 | 2021 | 1102 | 0.420 |
Why?
|
| Virus Assembly | 1 | 2014 | 22 | 0.420 |
Why?
|
| Immediate-Early Proteins | 2 | 2006 | 161 | 0.420 |
Why?
|
| Phenotype | 7 | 2014 | 2543 | 0.410 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 26 | 0.410 |
Why?
|
| Fetus | 3 | 2013 | 235 | 0.400 |
Why?
|
| Mesoderm | 2 | 2004 | 121 | 0.400 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2013 | 554 | 0.390 |
Why?
|
| Colitis | 4 | 2022 | 261 | 0.390 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 4 | 2015 | 48 | 0.390 |
Why?
|
| Erythropoietin | 6 | 1995 | 90 | 0.390 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2024 | 166 | 0.390 |
Why?
|
| Cell Nucleus | 5 | 2025 | 602 | 0.390 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2025 | 281 | 0.390 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2016 | 116 | 0.380 |
Why?
|
| Pyrimidines | 3 | 2024 | 384 | 0.380 |
Why?
|
| Niclosamide | 3 | 2018 | 10 | 0.370 |
Why?
|
| RNA, Messenger | 18 | 2022 | 2020 | 0.370 |
Why?
|
| Fracture Healing | 3 | 2017 | 43 | 0.370 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 3158 | 0.370 |
Why?
|
| Janus Kinase 1 | 1 | 2012 | 15 | 0.370 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 155 | 0.370 |
Why?
|
| Nanocomposites | 2 | 2024 | 16 | 0.370 |
Why?
|
| Durapatite | 5 | 2025 | 36 | 0.370 |
Why?
|
| Cloning, Organism | 1 | 2012 | 19 | 0.370 |
Why?
|
| Cartilage, Articular | 5 | 2024 | 77 | 0.360 |
Why?
|
| Embryo, Mammalian | 6 | 2015 | 217 | 0.360 |
Why?
|
| Down-Regulation | 7 | 2020 | 523 | 0.360 |
Why?
|
| Growth Hormone | 1 | 2012 | 97 | 0.360 |
Why?
|
| Intestinal Mucosa | 4 | 2022 | 824 | 0.360 |
Why?
|
| Mice, Inbred C3H | 7 | 2012 | 369 | 0.360 |
Why?
|
| Cell Lineage | 6 | 2013 | 320 | 0.360 |
Why?
|
| Wound Healing | 5 | 2022 | 373 | 0.360 |
Why?
|
| Piperazines | 2 | 2004 | 284 | 0.350 |
Why?
|
| Culture Media, Conditioned | 6 | 2016 | 103 | 0.350 |
Why?
|
| Proteolysis | 3 | 2024 | 123 | 0.350 |
Why?
|
| Endothelium, Vascular | 2 | 2025 | 436 | 0.350 |
Why?
|
| Panax notoginseng | 4 | 2016 | 23 | 0.350 |
Why?
|
| Osteoprotegerin | 3 | 2019 | 10 | 0.350 |
Why?
|
| Bone Morphogenetic Protein 3 | 3 | 2022 | 6 | 0.350 |
Why?
|
| Osteoclasts | 5 | 2020 | 35 | 0.340 |
Why?
|
| Pluripotent Stem Cells | 2 | 2009 | 37 | 0.340 |
Why?
|
| Intervertebral Disc Degeneration | 3 | 2025 | 63 | 0.340 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 155 | 0.340 |
Why?
|
| Immunohistochemistry | 11 | 2018 | 1790 | 0.340 |
Why?
|
| Ovarian Neoplasms | 4 | 2021 | 797 | 0.330 |
Why?
|
| Benzylisoquinolines | 1 | 2010 | 3 | 0.330 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 59 | 0.330 |
Why?
|
| Intestines | 1 | 2014 | 432 | 0.330 |
Why?
|
| DNA Primers | 5 | 2022 | 528 | 0.330 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2025 | 131 | 0.330 |
Why?
|
| Bone Diseases | 1 | 2011 | 52 | 0.330 |
Why?
|
| Activin Receptors, Type I | 1 | 2010 | 13 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2021 | 457 | 0.320 |
Why?
|
| Acyltransferases | 1 | 2010 | 52 | 0.320 |
Why?
|
| Integrases | 3 | 2014 | 66 | 0.320 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 4 | 2013 | 23 | 0.310 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2017 | 657 | 0.310 |
Why?
|
| Heterografts | 5 | 2021 | 116 | 0.310 |
Why?
|
| Transforming Growth Factor beta | 5 | 2008 | 347 | 0.310 |
Why?
|
| Urine | 3 | 2024 | 94 | 0.310 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2017 | 392 | 0.310 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2019 | 45 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 12 | 2015 | 1025 | 0.300 |
Why?
|
| Base Sequence | 10 | 2014 | 2209 | 0.300 |
Why?
|
| Chondrosarcoma | 2 | 2021 | 41 | 0.300 |
Why?
|
| Mebendazole | 2 | 2021 | 8 | 0.300 |
Why?
|
| Antinematodal Agents | 2 | 2021 | 9 | 0.300 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2023 | 179 | 0.300 |
Why?
|
| Tooth | 2 | 2020 | 56 | 0.300 |
Why?
|
| Myoblasts | 1 | 2009 | 33 | 0.300 |
Why?
|
| Osteocytes | 2 | 2012 | 8 | 0.300 |
Why?
|
| PPAR gamma | 4 | 2012 | 75 | 0.290 |
Why?
|
| Enzyme Inhibitors | 5 | 2013 | 639 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2003 | 665 | 0.290 |
Why?
|
| Genes, APC | 2 | 1999 | 25 | 0.290 |
Why?
|
| Biomarkers | 13 | 2020 | 1912 | 0.290 |
Why?
|
| Transcription, Genetic | 6 | 2013 | 1115 | 0.290 |
Why?
|
| Microspheres | 3 | 2025 | 88 | 0.290 |
Why?
|
| Bone Morphogenetic Protein 7 | 4 | 2015 | 13 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2018 | 1913 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2016 | 454 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 11 | 2025 | 3430 | 0.280 |
Why?
|
| X-Ray Microtomography | 5 | 2021 | 101 | 0.280 |
Why?
|
| Amyloid beta-Peptides | 2 | 2022 | 245 | 0.280 |
Why?
|
| Colon | 3 | 2024 | 540 | 0.280 |
Why?
|
| Membrane Proteins | 4 | 2024 | 1260 | 0.280 |
Why?
|
| Models, Biological | 6 | 2009 | 1768 | 0.280 |
Why?
|
| Thiazoles | 3 | 2013 | 124 | 0.280 |
Why?
|
| Phosphorylation | 11 | 2018 | 1130 | 0.270 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2024 | 214 | 0.270 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2019 | 83 | 0.270 |
Why?
|
| Protein Isoforms | 1 | 2009 | 295 | 0.270 |
Why?
|
| Lipid Metabolism | 3 | 2025 | 214 | 0.270 |
Why?
|
| Kidney | 8 | 2018 | 1110 | 0.270 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 740 | 0.270 |
Why?
|
| Angiotensin II | 2 | 2018 | 94 | 0.270 |
Why?
|
| Receptor, Notch1 | 2 | 2019 | 101 | 0.270 |
Why?
|
| Calcification, Physiologic | 4 | 2019 | 33 | 0.270 |
Why?
|
| Enzyme Activation | 8 | 2013 | 672 | 0.260 |
Why?
|
| Time Factors | 10 | 2015 | 5406 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2015 | 416 | 0.260 |
Why?
|
| Transgenes | 4 | 2019 | 171 | 0.260 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2023 | 318 | 0.260 |
Why?
|
| Magnetite Nanoparticles | 2 | 2018 | 26 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 6 | 2014 | 959 | 0.250 |
Why?
|
| Recombinant Proteins | 9 | 2022 | 982 | 0.250 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2007 | 123 | 0.250 |
Why?
|
| Drug Therapy | 1 | 2007 | 68 | 0.250 |
Why?
|
| Luciferases | 3 | 2010 | 129 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 636 | 0.240 |
Why?
|
| Lithium | 2 | 2024 | 61 | 0.240 |
Why?
|
| Hypertension | 3 | 2019 | 758 | 0.240 |
Why?
|
| Bone Matrix | 3 | 2022 | 20 | 0.240 |
Why?
|
| Disease | 1 | 2007 | 92 | 0.240 |
Why?
|
| Gene Silencing | 6 | 2020 | 177 | 0.240 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 378 | 0.240 |
Why?
|
| Proteome | 2 | 2018 | 153 | 0.240 |
Why?
|
| Calcium Phosphates | 2 | 2019 | 84 | 0.230 |
Why?
|
| Homeostasis | 3 | 2022 | 460 | 0.230 |
Why?
|
| Periodontal Ligament | 2 | 2022 | 3 | 0.230 |
Why?
|
| Ultrasonic Therapy | 2 | 2016 | 42 | 0.230 |
Why?
|
| Smad Proteins | 5 | 2013 | 42 | 0.230 |
Why?
|
| ErbB Receptors | 3 | 2018 | 506 | 0.230 |
Why?
|
| Regeneration | 2 | 2025 | 159 | 0.230 |
Why?
|
| Transistors, Electronic | 1 | 2025 | 6 | 0.230 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2009 | 691 | 0.230 |
Why?
|
| Fruit | 4 | 2009 | 81 | 0.220 |
Why?
|
| Extracellular Matrix | 6 | 2025 | 250 | 0.220 |
Why?
|
| Annulus Fibrosus | 1 | 2025 | 6 | 0.220 |
Why?
|
| Nucleus Pulposus | 1 | 2025 | 6 | 0.220 |
Why?
|
| Embryonic Stem Cells | 3 | 2014 | 85 | 0.220 |
Why?
|
| Vasodilation | 1 | 2025 | 91 | 0.220 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2024 | 7 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2017 | 151 | 0.220 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2018 | 147 | 0.220 |
Why?
|
| Cell Communication | 2 | 2017 | 216 | 0.220 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 15 | 0.220 |
Why?
|
| Coculture Techniques | 5 | 2019 | 170 | 0.220 |
Why?
|
| Virus Replication | 3 | 2017 | 284 | 0.220 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2024 | 3 | 0.220 |
Why?
|
| Dental Papilla | 2 | 2014 | 6 | 0.210 |
Why?
|
| Acetabulum | 1 | 2024 | 21 | 0.210 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2024 | 17 | 0.210 |
Why?
|
| Gelatin | 4 | 2017 | 27 | 0.210 |
Why?
|
| Face | 2 | 2017 | 109 | 0.210 |
Why?
|
| Enteroendocrine Cells | 1 | 2024 | 8 | 0.210 |
Why?
|
| CD11c Antigen | 1 | 2024 | 20 | 0.210 |
Why?
|
| Sympathectomy | 2 | 2015 | 19 | 0.210 |
Why?
|
| I-kappa B Proteins | 2 | 2005 | 47 | 0.210 |
Why?
|
| Thiazolidinediones | 2 | 2018 | 77 | 0.210 |
Why?
|
| Lower Extremity | 1 | 2025 | 99 | 0.210 |
Why?
|
| Chitosan | 3 | 2019 | 17 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 2 | 2025 | 304 | 0.210 |
Why?
|
| Walking | 1 | 2025 | 104 | 0.210 |
Why?
|
| Morpholines | 1 | 2024 | 61 | 0.210 |
Why?
|
| Biosensing Techniques | 1 | 2025 | 81 | 0.210 |
Why?
|
| Tetracycline | 1 | 2004 | 13 | 0.210 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 590 | 0.210 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 50 | 0.210 |
Why?
|
| Tooth Germ | 2 | 2021 | 6 | 0.210 |
Why?
|
| Point-of-Care Systems | 1 | 2025 | 150 | 0.210 |
Why?
|
| Calcium-Binding Proteins | 4 | 2020 | 119 | 0.210 |
Why?
|
| Aorta | 1 | 2025 | 273 | 0.200 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 119 | 0.200 |
Why?
|
| Random Allocation | 4 | 2017 | 307 | 0.200 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2023 | 45 | 0.200 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2003 | 10 | 0.200 |
Why?
|
| Rabbits | 8 | 2024 | 613 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2024 | 304 | 0.200 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 554 | 0.200 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2023 | 33 | 0.200 |
Why?
|
| S100 Calcium Binding Protein A6 | 3 | 2015 | 12 | 0.190 |
Why?
|
| Calgranulin B | 2 | 2013 | 16 | 0.190 |
Why?
|
| Mutation | 8 | 2013 | 4266 | 0.190 |
Why?
|
| Epidermal Growth Factor | 2 | 2013 | 115 | 0.190 |
Why?
|
| CELF1 Protein | 1 | 2022 | 1 | 0.190 |
Why?
|
| Prostatic Neoplasms | 2 | 2024 | 1775 | 0.190 |
Why?
|
| Protein Engineering | 1 | 2004 | 149 | 0.190 |
Why?
|
| Hepatitis B | 1 | 2003 | 77 | 0.190 |
Why?
|
| Caspase 3 | 4 | 2017 | 161 | 0.190 |
Why?
|
| Citric Acid | 2 | 2024 | 47 | 0.190 |
Why?
|
| Meningioma | 1 | 2023 | 62 | 0.190 |
Why?
|
| Meningeal Neoplasms | 1 | 2023 | 69 | 0.190 |
Why?
|
| Sublingual Gland | 1 | 2022 | 1 | 0.190 |
Why?
|
| Glycoproteins | 2 | 2017 | 217 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 4 | 2025 | 836 | 0.190 |
Why?
|
| Glypicans | 1 | 2022 | 7 | 0.190 |
Why?
|
| Rats | 6 | 2025 | 4042 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2024 | 319 | 0.180 |
Why?
|
| Obesity | 2 | 2024 | 1019 | 0.180 |
Why?
|
| Chromans | 1 | 2002 | 28 | 0.180 |
Why?
|
| Achilles Tendon | 2 | 2016 | 17 | 0.180 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2019 | 60 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2024 | 1584 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 4 | 2021 | 254 | 0.180 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 15 | 0.180 |
Why?
|
| Acetylcholine | 1 | 2022 | 158 | 0.180 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2013 | 306 | 0.180 |
Why?
|
| Antioxidants | 3 | 2018 | 231 | 0.180 |
Why?
|
| Cytoplasm | 1 | 2002 | 277 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 1077 | 0.180 |
Why?
|
| High Mobility Group Proteins | 3 | 2007 | 27 | 0.180 |
Why?
|
| HeLa Cells | 7 | 2017 | 517 | 0.180 |
Why?
|
| Fibrinolysis | 1 | 2022 | 36 | 0.180 |
Why?
|
| Cisplatin | 2 | 2021 | 568 | 0.170 |
Why?
|
| Zebrafish Proteins | 1 | 2003 | 159 | 0.170 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 1661 | 0.170 |
Why?
|
| Disease Progression | 3 | 2025 | 1531 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2021 | 2 | 0.170 |
Why?
|
| Tamoxifen | 1 | 2022 | 170 | 0.170 |
Why?
|
| Fluorouracil | 3 | 2015 | 524 | 0.170 |
Why?
|
| Oxidative Stress | 2 | 2016 | 467 | 0.170 |
Why?
|
| Fibrosis | 2 | 2022 | 230 | 0.170 |
Why?
|
| Kruppel-Like Factor 6 | 1 | 2021 | 5 | 0.170 |
Why?
|
| Sp1 Transcription Factor | 1 | 2021 | 24 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 660 | 0.170 |
Why?
|
| Schwann Cells | 1 | 2021 | 34 | 0.170 |
Why?
|
| Photochemotherapy | 1 | 2021 | 100 | 0.170 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 49 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 6 | 2017 | 890 | 0.160 |
Why?
|
| Nitric Oxide | 1 | 2022 | 281 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2021 | 69 | 0.160 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 73 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2019 | 113 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 41 | 0.160 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 4 | 2017 | 63 | 0.160 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 40 | 0.160 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2020 | 6 | 0.160 |
Why?
|
| NLR Proteins | 1 | 2020 | 3 | 0.160 |
Why?
|
| Cell Separation | 4 | 2014 | 200 | 0.160 |
Why?
|
| Neural Stem Cells | 1 | 2021 | 69 | 0.160 |
Why?
|
| Collagen Type I | 3 | 2019 | 74 | 0.160 |
Why?
|
| Connective Tissue Growth Factor | 2 | 2014 | 16 | 0.160 |
Why?
|
| Nomograms | 1 | 2020 | 34 | 0.160 |
Why?
|
| Penile Neoplasms | 1 | 2020 | 19 | 0.160 |
Why?
|
| Anticarcinogenic Agents | 2 | 2013 | 71 | 0.160 |
Why?
|
| Cell Hypoxia | 2 | 2021 | 187 | 0.160 |
Why?
|
| Drug Discovery | 2 | 2024 | 113 | 0.160 |
Why?
|
| beta-Arrestin 1 | 1 | 2019 | 6 | 0.160 |
Why?
|
| Mice, Knockout | 5 | 2025 | 2121 | 0.160 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2019 | 16 | 0.160 |
Why?
|
| Dendritic Cells | 1 | 2024 | 536 | 0.150 |
Why?
|
| alpha-Fetoproteins | 2 | 2017 | 45 | 0.150 |
Why?
|
| Sulindac | 1 | 1999 | 8 | 0.150 |
Why?
|
| Middle Aged | 15 | 2025 | 27621 | 0.150 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 2718 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2019 | 188 | 0.150 |
Why?
|
| Organ Culture Techniques | 3 | 2015 | 120 | 0.150 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 538 | 0.150 |
Why?
|
| Bone Resorption | 1 | 2019 | 43 | 0.150 |
Why?
|
| Dentin | 1 | 2019 | 9 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 4 | 2004 | 435 | 0.150 |
Why?
|
| Ultrasonography | 2 | 2019 | 702 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 494 | 0.150 |
Why?
|
| Liver Neoplasms | 3 | 2015 | 774 | 0.150 |
Why?
|
| Protein Binding | 4 | 2010 | 1528 | 0.150 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 66 | 0.150 |
Why?
|
| Glycogen Synthase Kinase 3 | 3 | 2013 | 69 | 0.140 |
Why?
|
| Transplantation Conditioning | 1 | 2021 | 383 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2018 | 244 | 0.140 |
Why?
|
| Materials Testing | 2 | 2016 | 96 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 86 | 0.140 |
Why?
|
| Axons | 1 | 2019 | 178 | 0.140 |
Why?
|
| Neurogenesis | 2 | 2010 | 89 | 0.140 |
Why?
|
| KRIT1 Protein | 1 | 2018 | 62 | 0.140 |
Why?
|
| Glioma | 2 | 2013 | 300 | 0.140 |
Why?
|
| Genes, myc | 1 | 1998 | 37 | 0.140 |
Why?
|
| Twist Transcription Factors | 1 | 2018 | 2 | 0.140 |
Why?
|
| Umbilical Cord | 1 | 2018 | 39 | 0.140 |
Why?
|
| Integrin beta3 | 1 | 2018 | 31 | 0.140 |
Why?
|
| Molecular Sequence Data | 11 | 2013 | 2889 | 0.140 |
Why?
|
| Myosin Type II | 1 | 2018 | 50 | 0.140 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 505 | 0.140 |
Why?
|
| Fracture Fixation, Internal | 2 | 2016 | 89 | 0.140 |
Why?
|
| Azacitidine | 2 | 2018 | 149 | 0.140 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 620 | 0.140 |
Why?
|
| Strontium | 1 | 2018 | 5 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2016 | 364 | 0.140 |
Why?
|
| Cell Membrane Permeability | 1 | 2018 | 121 | 0.140 |
Why?
|
| Temperature | 2 | 2018 | 423 | 0.140 |
Why?
|
| Motion | 1 | 2018 | 94 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2009 | 106 | 0.140 |
Why?
|
| Niacinamide | 1 | 2018 | 101 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 7 | 2018 | 304 | 0.140 |
Why?
|
| ADAM10 Protein | 1 | 2017 | 8 | 0.140 |
Why?
|
| HT29 Cells | 5 | 2009 | 49 | 0.140 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2013 | 123 | 0.140 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 490 | 0.130 |
Why?
|
| Peptides, Cyclic | 1 | 2018 | 40 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 555 | 0.130 |
Why?
|
| Proteomics | 2 | 2018 | 264 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 305 | 0.130 |
Why?
|
| Plasmids | 5 | 2018 | 272 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2018 | 88 | 0.130 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 97 | 0.130 |
Why?
|
| Deoxycytidine | 1 | 2018 | 208 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 297 | 0.130 |
Why?
|
| Sarcoma | 2 | 2013 | 222 | 0.130 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2017 | 4 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 249 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 2018 | 67 | 0.130 |
Why?
|
| Plant Roots | 7 | 2017 | 112 | 0.130 |
Why?
|
| Adenylyl Cyclases | 1 | 2017 | 105 | 0.130 |
Why?
|
| Eye Proteins | 1 | 2018 | 130 | 0.130 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2017 | 8 | 0.130 |
Why?
|
| Hand Deformities, Congenital | 1 | 2017 | 15 | 0.130 |
Why?
|
| Transformation, Genetic | 1 | 2017 | 38 | 0.130 |
Why?
|
| Dwarfism | 1 | 2017 | 13 | 0.130 |
Why?
|
| rho-Associated Kinases | 1 | 2018 | 161 | 0.130 |
Why?
|
| Genitalia, Male | 1 | 2017 | 24 | 0.130 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 23 | 0.130 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 373 | 0.130 |
Why?
|
| Phosphates | 1 | 2018 | 163 | 0.130 |
Why?
|
| Osseointegration | 1 | 2017 | 10 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 56 | 0.130 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2019 | 105 | 0.130 |
Why?
|
| Nylons | 1 | 2016 | 7 | 0.130 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2017 | 36 | 0.130 |
Why?
|
| Pancreas | 1 | 2018 | 258 | 0.130 |
Why?
|
| Silver | 1 | 2016 | 16 | 0.130 |
Why?
|
| Interleukin-8 | 2 | 2015 | 88 | 0.130 |
Why?
|
| Heat-Shock Proteins | 2 | 2016 | 177 | 0.130 |
Why?
|
| Titanium | 1 | 2016 | 27 | 0.130 |
Why?
|
| Retroviridae | 1 | 2017 | 73 | 0.130 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2016 | 20 | 0.120 |
Why?
|
| Wnt-5a Protein | 1 | 2016 | 10 | 0.120 |
Why?
|
| Choristoma | 2 | 2013 | 59 | 0.120 |
Why?
|
| Oncogene Protein v-akt | 2 | 2014 | 21 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 5 | 2012 | 292 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2020 | 548 | 0.120 |
Why?
|
| Carotid Body | 1 | 2019 | 241 | 0.120 |
Why?
|
| Collagen | 2 | 2016 | 300 | 0.120 |
Why?
|
| Acrylic Resins | 1 | 2016 | 24 | 0.120 |
Why?
|
| Cadherins | 1 | 2017 | 180 | 0.120 |
Why?
|
| Tenocytes | 1 | 2016 | 4 | 0.120 |
Why?
|
| Citrates | 1 | 2016 | 28 | 0.120 |
Why?
|
| Fractures, Malunited | 1 | 2016 | 6 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2013 | 68 | 0.120 |
Why?
|
| Coffee | 1 | 2016 | 10 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 87 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 203 | 0.120 |
Why?
|
| Butyrates | 1 | 2016 | 56 | 0.120 |
Why?
|
| Bone Morphogenetic Protein 6 | 2 | 2007 | 10 | 0.120 |
Why?
|
| Telomerase | 2 | 2013 | 67 | 0.120 |
Why?
|
| Cattle | 6 | 2019 | 394 | 0.120 |
Why?
|
| Osteocalcin | 3 | 2012 | 25 | 0.120 |
Why?
|
| Lipids | 2 | 2023 | 278 | 0.120 |
Why?
|
| Osteotomy | 1 | 2016 | 43 | 0.120 |
Why?
|
| Ilium | 1 | 2016 | 30 | 0.120 |
Why?
|
| B7-2 Antigen | 1 | 2015 | 42 | 0.120 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2016 | 92 | 0.120 |
Why?
|
| Humeral Fractures | 1 | 2016 | 25 | 0.120 |
Why?
|
| Osteopontin | 3 | 2012 | 48 | 0.120 |
Why?
|
| Pelvic Bones | 1 | 2016 | 45 | 0.120 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2015 | 57 | 0.110 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 91 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 192 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 78 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 170 | 0.110 |
Why?
|
| DNA Damage | 2 | 2016 | 389 | 0.110 |
Why?
|
| Histones | 3 | 2024 | 361 | 0.110 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2018 | 259 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2013 | 812 | 0.110 |
Why?
|
| Transcriptional Activation | 5 | 2018 | 290 | 0.110 |
Why?
|
| RANK Ligand | 2 | 2014 | 11 | 0.110 |
Why?
|
| Binding Sites | 4 | 2007 | 1128 | 0.110 |
Why?
|
| Anthelmintics | 1 | 2015 | 6 | 0.110 |
Why?
|
| Pancreatectomy | 1 | 2016 | 168 | 0.110 |
Why?
|
| Hepatitis B virus | 2 | 2006 | 47 | 0.110 |
Why?
|
| Cloning, Molecular | 3 | 2019 | 578 | 0.110 |
Why?
|
| Adolescent | 8 | 2020 | 9610 | 0.110 |
Why?
|
| Models, Animal | 2 | 2015 | 281 | 0.110 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 25 | 0.110 |
Why?
|
| Structure-Activity Relationship | 3 | 2024 | 423 | 0.110 |
Why?
|
| Gentian Violet | 2 | 2013 | 9 | 0.110 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 64 | 0.110 |
Why?
|
| Caspases | 2 | 2012 | 151 | 0.110 |
Why?
|
| Tetrazolium Salts | 2 | 2013 | 11 | 0.110 |
Why?
|
| Cell Death | 2 | 2013 | 253 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 256 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2024 | 443 | 0.110 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 102 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 111 | 0.110 |
Why?
|
| Twist-Related Protein 1 | 1 | 2014 | 16 | 0.110 |
Why?
|
| Adenoviridae Infections | 1 | 2014 | 16 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 3 | 2025 | 99 | 0.100 |
Why?
|
| Hippocampus | 1 | 2017 | 452 | 0.100 |
Why?
|
| Infant | 2 | 2020 | 3222 | 0.100 |
Why?
|
| Cadmium Compounds | 1 | 2014 | 2 | 0.100 |
Why?
|
| Selenium Compounds | 1 | 2014 | 3 | 0.100 |
Why?
|
| Zinc Compounds | 1 | 2014 | 6 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 361 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2015 | 896 | 0.100 |
Why?
|
| Quantum Dots | 1 | 2014 | 19 | 0.100 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 264 | 0.100 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2013 | 3 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 367 | 0.100 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Epithelial Cells | 2 | 2016 | 700 | 0.100 |
Why?
|
| Adenocarcinoma | 3 | 2007 | 1173 | 0.100 |
Why?
|
| Luminescent Proteins | 4 | 2003 | 141 | 0.100 |
Why?
|
| Sarcoma, Synovial | 1 | 2013 | 20 | 0.100 |
Why?
|
| Lasers | 1 | 2014 | 101 | 0.100 |
Why?
|
| Sulfides | 1 | 2014 | 68 | 0.100 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 256 | 0.100 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2013 | 121 | 0.100 |
Why?
|
| Primary Cell Culture | 3 | 2020 | 83 | 0.100 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1993 | 63 | 0.100 |
Why?
|
| Artemisinins | 1 | 2013 | 6 | 0.100 |
Why?
|
| Mammals | 3 | 2022 | 259 | 0.100 |
Why?
|
| Subrenal Capsule Assay | 1 | 2013 | 3 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 1233 | 0.100 |
Why?
|
| Imatinib Mesylate | 2 | 2004 | 127 | 0.100 |
Why?
|
| Genistein | 1 | 2013 | 16 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Receptor Cross-Talk | 1 | 2013 | 33 | 0.100 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 2013 | 7 | 0.100 |
Why?
|
| Luciferases, Firefly | 2 | 2012 | 12 | 0.100 |
Why?
|
| Calgranulin A | 1 | 2013 | 11 | 0.100 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 147 | 0.100 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2013 | 64 | 0.100 |
Why?
|
| Kinetics | 4 | 2025 | 1470 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 98 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 546 | 0.100 |
Why?
|
| Estrogens | 1 | 2013 | 195 | 0.090 |
Why?
|
| Estradiol | 1 | 2013 | 247 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 371 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 174 | 0.090 |
Why?
|
| Amino Acid Sequence | 7 | 2013 | 1993 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 603 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 308 | 0.090 |
Why?
|
| Adult | 12 | 2025 | 27955 | 0.090 |
Why?
|
| Benzamides | 2 | 2004 | 246 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2012 | 42 | 0.090 |
Why?
|
| PAX3 Transcription Factor | 1 | 2012 | 11 | 0.090 |
Why?
|
| Hot Temperature | 3 | 2009 | 217 | 0.090 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2012 | 14 | 0.090 |
Why?
|
| Adenomatous Polyposis Coli Protein | 4 | 2000 | 42 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 50 | 0.090 |
Why?
|
| Smad4 Protein | 2 | 2019 | 26 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 86 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 37 | 0.090 |
Why?
|
| Electromagnetic Fields | 1 | 2012 | 26 | 0.090 |
Why?
|
| Appetite | 1 | 2012 | 21 | 0.090 |
Why?
|
| Catechin | 1 | 2012 | 22 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2012 | 80 | 0.090 |
Why?
|
| Viral Core Proteins | 1 | 2011 | 24 | 0.090 |
Why?
|
| Urology | 1 | 2013 | 133 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 121 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 253 | 0.090 |
Why?
|
| Perfusion | 1 | 2013 | 260 | 0.090 |
Why?
|
| Malonates | 1 | 2011 | 11 | 0.090 |
Why?
|
| Collagen Type II | 2 | 2009 | 16 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 201 | 0.090 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 225 | 0.080 |
Why?
|
| TCF Transcription Factors | 3 | 2000 | 24 | 0.080 |
Why?
|
| Camptothecin | 1 | 2012 | 196 | 0.080 |
Why?
|
| Interferon Type I | 1 | 2012 | 164 | 0.080 |
Why?
|
| Extremities | 3 | 2013 | 172 | 0.080 |
Why?
|
| Immunotherapy | 3 | 2024 | 761 | 0.080 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 3 | 2000 | 32 | 0.080 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2010 | 32 | 0.080 |
Why?
|
| 3' Untranslated Regions | 2 | 2022 | 98 | 0.080 |
Why?
|
| Hep G2 Cells | 3 | 2021 | 53 | 0.080 |
Why?
|
| Activin Receptors, Type II | 1 | 2010 | 9 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2011 | 135 | 0.080 |
Why?
|
| Range of Motion, Articular | 2 | 2025 | 178 | 0.080 |
Why?
|
| Janus Kinase 2 | 6 | 1996 | 59 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 1923 | 0.080 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2010 | 4 | 0.080 |
Why?
|
| Growth and Development | 1 | 2010 | 14 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 398 | 0.080 |
Why?
|
| Heart | 1 | 2013 | 522 | 0.080 |
Why?
|
| Sirtuins | 1 | 2011 | 79 | 0.080 |
Why?
|
| RNA | 2 | 2004 | 572 | 0.080 |
Why?
|
| Lysine | 1 | 2011 | 182 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2013 | 660 | 0.080 |
Why?
|
| Dental Pulp | 2 | 2020 | 5 | 0.080 |
Why?
|
| Corydalis | 1 | 2009 | 4 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 1073 | 0.080 |
Why?
|
| Reactive Oxygen Species | 4 | 2016 | 502 | 0.080 |
Why?
|
| Antigens, Differentiation | 3 | 2016 | 124 | 0.080 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2009 | 16 | 0.070 |
Why?
|
| Tyrosine Transaminase | 3 | 2015 | 3 | 0.070 |
Why?
|
| Aggrecans | 1 | 2009 | 20 | 0.070 |
Why?
|
| Wnt1 Protein | 2 | 2013 | 27 | 0.070 |
Why?
|
| Osteoblastoma | 1 | 2009 | 6 | 0.070 |
Why?
|
| Chemoprevention | 2 | 2013 | 93 | 0.070 |
Why?
|
| Oncolytic Viruses | 1 | 2009 | 20 | 0.070 |
Why?
|
| Wnt3 Protein | 2 | 2009 | 13 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2010 | 241 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2010 | 146 | 0.070 |
Why?
|
| Drug Repositioning | 2 | 2021 | 26 | 0.070 |
Why?
|
| Polymers | 2 | 2025 | 218 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 3 | 2013 | 43 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2009 | 36 | 0.070 |
Why?
|
| Protein Stability | 3 | 2014 | 103 | 0.070 |
Why?
|
| Indoles | 2 | 2025 | 301 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 408 | 0.070 |
Why?
|
| Escherichia coli | 3 | 2016 | 562 | 0.070 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2008 | 5 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 172 | 0.070 |
Why?
|
| RecQ Helicases | 1 | 2008 | 8 | 0.070 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2021 | 67 | 0.070 |
Why?
|
| Neurofibromatosis 2 | 1 | 2008 | 13 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2008 | 60 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2012 | 585 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2012 | 456 | 0.070 |
Why?
|
| Retinoblastoma Protein | 1 | 2008 | 68 | 0.070 |
Why?
|
| Spiral Cone-Beam Computed Tomography | 1 | 2007 | 8 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 185 | 0.070 |
Why?
|
| Neurons | 2 | 2021 | 1575 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2016 | 2544 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1103 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2019 | 947 | 0.070 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2007 | 27 | 0.060 |
Why?
|
| Survival Rate | 3 | 2015 | 1950 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 63 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2005 | 38 | 0.060 |
Why?
|
| Retinoic Acid Receptor alpha | 3 | 2012 | 18 | 0.060 |
Why?
|
| Odontoblasts | 2 | 2019 | 9 | 0.060 |
Why?
|
| Child | 5 | 2019 | 7359 | 0.060 |
Why?
|
| Tensile Strength | 1 | 2007 | 86 | 0.060 |
Why?
|
| SOX9 Transcription Factor | 4 | 2009 | 27 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2023 | 460 | 0.060 |
Why?
|
| Indocyanine Green | 2 | 2019 | 25 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1933 | 0.060 |
Why?
|
| Nestin | 2 | 2021 | 17 | 0.060 |
Why?
|
| Interleukin-3 | 3 | 1995 | 39 | 0.060 |
Why?
|
| Genetic Techniques | 1 | 2007 | 74 | 0.060 |
Why?
|
| Growth Substances | 1 | 2006 | 79 | 0.060 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2006 | 5 | 0.060 |
Why?
|
| Proteins | 2 | 2004 | 800 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 53 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2019 | 3832 | 0.060 |
Why?
|
| DNA Fingerprinting | 1 | 2005 | 18 | 0.060 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 139 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 2018 | 0.060 |
Why?
|
| Hypertrophy | 2 | 2019 | 67 | 0.060 |
Why?
|
| Dextran Sulfate | 2 | 2017 | 70 | 0.060 |
Why?
|
| Thromboxane A2 | 1 | 2025 | 11 | 0.060 |
Why?
|
| Azoxymethane | 2 | 2017 | 84 | 0.060 |
Why?
|
| Mitogens | 2 | 1996 | 59 | 0.060 |
Why?
|
| Fusobacterium nucleatum | 1 | 2025 | 4 | 0.060 |
Why?
|
| Mutagenesis | 3 | 1994 | 192 | 0.060 |
Why?
|
| Young Adult | 4 | 2025 | 6938 | 0.060 |
Why?
|
| Nucleocapsid Proteins | 1 | 2005 | 10 | 0.060 |
Why?
|
| Berberine | 1 | 2025 | 9 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2002 | 543 | 0.060 |
Why?
|
| Cyclins | 3 | 2008 | 80 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 3913 | 0.060 |
Why?
|
| Salmonella Infections | 1 | 2005 | 18 | 0.060 |
Why?
|
| Salmonella typhimurium | 1 | 2005 | 32 | 0.060 |
Why?
|
| Demethylation | 1 | 2024 | 12 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 990 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2005 | 122 | 0.050 |
Why?
|
| Hip Joint | 1 | 2025 | 56 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2024 | 11 | 0.050 |
Why?
|
| Gait | 1 | 2025 | 83 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2007 | 505 | 0.050 |
Why?
|
| Tendons | 1 | 2005 | 48 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2025 | 133 | 0.050 |
Why?
|
| Hydrazones | 1 | 2024 | 5 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 71 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2018 | 108 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2021 | 41 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1995 | 113 | 0.050 |
Why?
|
| Spinal Diseases | 1 | 2005 | 97 | 0.050 |
Why?
|
| Hyperphagia | 1 | 2024 | 35 | 0.050 |
Why?
|
| Particle Size | 1 | 2024 | 126 | 0.050 |
Why?
|
| Nanostructures | 1 | 2025 | 89 | 0.050 |
Why?
|
| Injections | 1 | 2024 | 124 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2005 | 111 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2024 | 109 | 0.050 |
Why?
|
| Glycogen | 2 | 2014 | 59 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 178 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2005 | 137 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 46 | 0.050 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2023 | 4 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2024 | 147 | 0.050 |
Why?
|
| Drug Design | 1 | 2004 | 133 | 0.050 |
Why?
|
| Proteoglycans | 2 | 2018 | 75 | 0.050 |
Why?
|
| Safety | 1 | 2004 | 132 | 0.050 |
Why?
|
| Keratin-18 | 2 | 2015 | 3 | 0.050 |
Why?
|
| Constriction | 1 | 2023 | 27 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2023 | 34 | 0.050 |
Why?
|
| Thymocytes | 1 | 2023 | 31 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2003 | 74 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2023 | 30 | 0.050 |
Why?
|
| Biomechanical Phenomena | 1 | 2025 | 489 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 60 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2020 | 697 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2023 | 45 | 0.050 |
Why?
|
| Fluid Therapy | 1 | 2023 | 66 | 0.050 |
Why?
|
| Aged | 7 | 2020 | 20469 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 183 | 0.050 |
Why?
|
| Vaccines | 1 | 2004 | 84 | 0.050 |
Why?
|
| Goals | 1 | 2023 | 67 | 0.050 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2003 | 49 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2003 | 129 | 0.050 |
Why?
|
| Androgens | 1 | 2023 | 162 | 0.050 |
Why?
|
| Bacteria | 1 | 2007 | 509 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 353 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2023 | 207 | 0.050 |
Why?
|
| Adenoma | 1 | 2005 | 258 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2002 | 66 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2022 | 20 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2002 | 85 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 143 | 0.050 |
Why?
|
| Cell Transplantation | 2 | 2015 | 46 | 0.050 |
Why?
|
| G1 Phase | 2 | 2012 | 64 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2005 | 1525 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 122 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 86 | 0.050 |
Why?
|
| Fibrinolysin | 1 | 2022 | 24 | 0.050 |
Why?
|
| Filgrastim | 1 | 2022 | 56 | 0.040 |
Why?
|
| Dogs | 2 | 2013 | 634 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 266 | 0.040 |
Why?
|
| Cell Shape | 2 | 2016 | 50 | 0.040 |
Why?
|
| Vacuoles | 2 | 2013 | 48 | 0.040 |
Why?
|
| Low-Level Light Therapy | 1 | 2021 | 15 | 0.040 |
Why?
|
| Bone Density | 1 | 2003 | 237 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2022 | 120 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2021 | 52 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2016 | 10186 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 158 | 0.040 |
Why?
|
| Retinoid X Receptor alpha | 2 | 2012 | 7 | 0.040 |
Why?
|
| Swine | 1 | 2022 | 587 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2024 | 379 | 0.040 |
Why?
|
| Exons | 1 | 2002 | 448 | 0.040 |
Why?
|
| Karyopherins | 1 | 2020 | 15 | 0.040 |
Why?
|
| Microarray Analysis | 2 | 2013 | 95 | 0.040 |
Why?
|
| Pyridines | 2 | 2013 | 302 | 0.040 |
Why?
|
| Exosomes | 1 | 2022 | 60 | 0.040 |
Why?
|
| Spinal Fusion | 1 | 2005 | 347 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 440 | 0.040 |
Why?
|
| Mitochondria | 2 | 2016 | 612 | 0.040 |
Why?
|
| Tooth Exfoliation | 1 | 2020 | 2 | 0.040 |
Why?
|
| Tooth, Deciduous | 1 | 2020 | 3 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2015 | 9108 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2022 | 282 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 156 | 0.040 |
Why?
|
| Oleic Acid | 1 | 2019 | 15 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 402 | 0.040 |
Why?
|
| Chromatin | 1 | 2023 | 440 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 688 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2018 | 2482 | 0.040 |
Why?
|
| Risk Factors | 3 | 2019 | 5912 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 235 | 0.040 |
Why?
|
| Glycosaminoglycans | 1 | 2019 | 31 | 0.040 |
Why?
|
| Dentinogenesis Imperfecta | 1 | 2019 | 1 | 0.040 |
Why?
|
| Ameloblasts | 1 | 2019 | 2 | 0.040 |
Why?
|
| Chondroitin Sulfates | 1 | 2019 | 27 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 99 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2022 | 282 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2019 | 31 | 0.040 |
Why?
|
| Triglycerides | 1 | 2019 | 231 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 2019 | 88 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2023 | 1006 | 0.040 |
Why?
|
| Incidence | 1 | 2023 | 1702 | 0.040 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2018 | 4 | 0.040 |
Why?
|
| Transposon Resolvases | 1 | 2018 | 7 | 0.040 |
Why?
|
| Fatty Liver | 1 | 2019 | 106 | 0.040 |
Why?
|
| Magnetic Fields | 1 | 2018 | 12 | 0.040 |
Why?
|
| Drug Liberation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 125 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 876 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 85 | 0.030 |
Why?
|
| Gene Regulatory Networks | 2 | 2013 | 317 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2018 | 51 | 0.030 |
Why?
|
| Collagen Type VI | 1 | 2018 | 4 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 889 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2015 | 379 | 0.030 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2018 | 7 | 0.030 |
Why?
|
| Liver Failure | 1 | 2018 | 69 | 0.030 |
Why?
|
| Exonucleases | 1 | 1997 | 9 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 578 | 0.030 |
Why?
|
| G2 Phase | 1 | 1997 | 31 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1997 | 41 | 0.030 |
Why?
|
| Periodic Acid | 1 | 2017 | 4 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 128 | 0.030 |
Why?
|
| Flowers | 2 | 2009 | 41 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1275 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2017 | 35 | 0.030 |
Why?
|
| Silicates | 1 | 2017 | 10 | 0.030 |
Why?
|
| Graphite | 1 | 2017 | 12 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 875 | 0.030 |
Why?
|
| Mitosis | 1 | 1997 | 150 | 0.030 |
Why?
|
| Liver Regeneration | 1 | 2017 | 34 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2017 | 74 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 848 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 215 | 0.030 |
Why?
|
| Virion | 1 | 2017 | 61 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 367 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1997 | 271 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2017 | 157 | 0.030 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Albumins | 1 | 2017 | 123 | 0.030 |
Why?
|
| Actin Cytoskeleton | 1 | 2018 | 196 | 0.030 |
Why?
|
| Antiparasitic Agents | 1 | 2016 | 9 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 2016 | 56 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 884 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1996 | 68 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 66 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 135 | 0.030 |
Why?
|
| Cartilage | 1 | 2016 | 71 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2016 | 91 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2016 | 51 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 1243 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 20 | 0.030 |
Why?
|
| Bone Plates | 1 | 2016 | 33 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2016 | 32 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1996 | 108 | 0.030 |
Why?
|
| Oncogenes | 1 | 1996 | 100 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 111 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2016 | 124 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 1999 | 556 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 476 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2015 | 35 | 0.030 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2015 | 29 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1007 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Lumbosacral Region | 1 | 2015 | 57 | 0.030 |
Why?
|
| Frontal Bone | 1 | 2015 | 16 | 0.030 |
Why?
|
| Low Back Pain | 1 | 2016 | 58 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2018 | 270 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1995 | 31 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2015 | 43 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 131 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 648 | 0.030 |
Why?
|
| Gossypol | 1 | 2014 | 5 | 0.030 |
Why?
|
| Tyrosine | 1 | 1995 | 131 | 0.030 |
Why?
|
| Growth Inhibitors | 2 | 2009 | 41 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 196 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 2016 | 98 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 210 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1049 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2016 | 167 | 0.030 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2015 | 80 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 1014 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2014 | 10 | 0.030 |
Why?
|
| Dependovirus | 1 | 2014 | 37 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2009 | 156 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2014 | 36 | 0.030 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2014 | 14 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 1 | 2014 | 23 | 0.030 |
Why?
|
| DNA Repair | 1 | 2016 | 361 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 205 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 657 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 863 | 0.030 |
Why?
|
| Absorption, Radiation | 1 | 2014 | 4 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 178 | 0.030 |
Why?
|
| Maleimides | 1 | 2013 | 27 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1993 | 119 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2015 | 519 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2014 | 122 | 0.030 |
Why?
|
| Baculoviridae | 1 | 1993 | 33 | 0.030 |
Why?
|
| Acetylation | 1 | 2014 | 149 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 89 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2014 | 57 | 0.030 |
Why?
|
| Molecular Weight | 1 | 1993 | 279 | 0.030 |
Why?
|
| Photons | 1 | 2014 | 48 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2016 | 284 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 291 | 0.030 |
Why?
|
| Apolipoprotein B-100 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Trypan Blue | 1 | 2013 | 3 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2013 | 84 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1993 | 161 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 89 | 0.020 |
Why?
|
| Saponins | 1 | 2013 | 41 | 0.020 |
Why?
|
| Moths | 1 | 1993 | 32 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2013 | 36 | 0.020 |
Why?
|
| Antimalarials | 1 | 2013 | 21 | 0.020 |
Why?
|
| Isoflavones | 1 | 2013 | 13 | 0.020 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2013 | 11 | 0.020 |
Why?
|
| Cytosol | 1 | 1993 | 192 | 0.020 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2013 | 14 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 193 | 0.020 |
Why?
|
| Clone Cells | 1 | 2013 | 219 | 0.020 |
Why?
|
| Renal Circulation | 1 | 2013 | 30 | 0.020 |
Why?
|
| Polyesters | 1 | 2013 | 44 | 0.020 |
Why?
|
| Epitopes | 1 | 1993 | 249 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2013 | 57 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2013 | 86 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 86 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2014 | 229 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 727 | 0.020 |
Why?
|
| Exome | 1 | 2013 | 141 | 0.020 |
Why?
|
| Renal Artery | 1 | 2013 | 45 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 84 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2013 | 76 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2013 | 104 | 0.020 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2012 | 5 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 186 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 416 | 0.020 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 42 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 107 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2012 | 20 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2012 | 19 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 138 | 0.020 |
Why?
|
| Telomere | 1 | 2013 | 120 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2012 | 47 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2014 | 280 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 66 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2023 | 2564 | 0.020 |
Why?
|
| Molecular Docking Simulation | 1 | 2012 | 57 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 726 | 0.020 |
Why?
|
| Catheterization | 1 | 2013 | 218 | 0.020 |
Why?
|
| Phosphoglycerate Kinase | 1 | 2011 | 14 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2011 | 39 | 0.020 |
Why?
|
| Succinates | 1 | 2011 | 25 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 79 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2013 | 311 | 0.020 |
Why?
|
| Graft Survival | 1 | 2015 | 938 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 303 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2013 | 237 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2011 | 126 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1994 | 661 | 0.020 |
Why?
|
| Horses | 1 | 2011 | 35 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2010 | 25 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2010 | 32 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 39 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 25 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 52 | 0.020 |
Why?
|
| Implants, Experimental | 1 | 2010 | 16 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 758 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 59 | 0.020 |
Why?
|
| Retinoid X Receptor gamma | 1 | 2010 | 1 | 0.020 |
Why?
|
| Retinoid X Receptor beta | 1 | 2010 | 1 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 73 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 34 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2011 | 190 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2011 | 179 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2009 | 24 | 0.020 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2009 | 24 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 2009 | 39 | 0.020 |
Why?
|
| Antibodies | 1 | 2011 | 347 | 0.020 |
Why?
|
| Collagen Type X | 1 | 2009 | 3 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2011 | 469 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1449 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2015 | 1122 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 891 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2009 | 8 | 0.020 |
Why?
|
| Eye Abnormalities | 1 | 2009 | 41 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2009 | 15 | 0.020 |
Why?
|
| Rhizome | 1 | 2009 | 7 | 0.020 |
Why?
|
| bcl-Associated Death Protein | 1 | 2009 | 18 | 0.020 |
Why?
|
| Neprilysin | 1 | 2009 | 39 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2010 | 405 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 33 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 1388 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 481 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 3061 | 0.020 |
Why?
|
| Heating | 1 | 2008 | 17 | 0.020 |
Why?
|
| Humerus | 1 | 2008 | 32 | 0.020 |
Why?
|
| Femoral Neoplasms | 1 | 2008 | 19 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3835 | 0.020 |
Why?
|
| Joints | 1 | 2008 | 32 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 7073 | 0.020 |
Why?
|
| Polymethyl Methacrylate | 1 | 2007 | 17 | 0.020 |
Why?
|
| Cyclin A | 1 | 2007 | 27 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 239 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 2375 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 2007 | 89 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 501 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 392 | 0.020 |
Why?
|
| Autophagy | 1 | 2009 | 172 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 1997 | 76 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2006 | 306 | 0.010 |
Why?
|
| Calcium | 1 | 2010 | 1175 | 0.010 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2005 | 8 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2005 | 4 | 0.010 |
Why?
|
| Luminescent Agents | 1 | 2005 | 6 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2007 | 484 | 0.010 |
Why?
|
| fas Receptor | 1 | 2005 | 73 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 147 | 0.010 |
Why?
|
| Tendon Injuries | 1 | 2005 | 39 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 234 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 2465 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Myoglobin | 1 | 2003 | 29 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 20 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 454 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 467 | 0.010 |
Why?
|
| CDX2 Transcription Factor | 1 | 1999 | 7 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 1954 | 0.010 |
Why?
|
| Exoribonucleases | 1 | 1997 | 9 | 0.010 |
Why?
|
| Polyploidy | 1 | 1997 | 15 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 1997 | 10 | 0.010 |
Why?
|
| Eukaryotic Cells | 1 | 1997 | 43 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1997 | 360 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1996 | 34 | 0.010 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 1996 | 20 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1996 | 65 | 0.010 |
Why?
|
| Alleles | 1 | 1999 | 1139 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 402 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1996 | 269 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1996 | 150 | 0.010 |
Why?
|
| Point Mutation | 1 | 1996 | 236 | 0.010 |
Why?
|
| United States | 1 | 2008 | 7645 | 0.010 |
Why?
|
| Terminator Regions, Genetic | 1 | 1994 | 12 | 0.010 |
Why?
|
| Reading Frames | 1 | 1994 | 6 | 0.010 |
Why?
|
| Receptors, Interleukin-3 | 1 | 1994 | 3 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1994 | 125 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1994 | 206 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 1997 | 877 | 0.010 |
Why?
|